190 related articles for article (PubMed ID: 38697174)
1. Targeting the EGFR signalling pathway in metastatic colorectal cancer.
Napolitano S; Martini G; Ciardiello D; Del Tufo S; Martinelli E; Troiani T; Ciardiello F
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):664-676. PubMed ID: 38697174
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.
Miyamoto Y; Suyama K; Baba H
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368335
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to EGFR-targeted therapies in colorectal cancer.
Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A
Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
Efferth T
Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
[TBL] [Abstract][Full Text] [Related]
5. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
Jeong WJ; Cha PH; Choi KY
World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
[TBL] [Abstract][Full Text] [Related]
6. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
Zhou J; Ji Q; Li Q
J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Sforza V; Martinelli E; Ciardiello F; Gambardella V; Napolitano S; Martini G; Della Corte C; Cardone C; Ferrara ML; Reginelli A; Liguori G; Belli G; Troiani T
World J Gastroenterol; 2016 Jul; 22(28):6345-61. PubMed ID: 27605871
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy.
González NS; Marchese PV; Baraibar I; Ros J; Salvà F; Rodríguez M; Salvà C; Vaghi C; Alcaraz A; García A; Tabernero J; Élez E
Expert Opin Investig Drugs; 2024 Jun; 33(6):613-625. PubMed ID: 38775361
[TBL] [Abstract][Full Text] [Related]
9. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in colorectal cancer: current status and future challenges.
Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
12. Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives.
Mizukami T; Izawa N; Nakajima TE; Sunakawa Y
Drugs; 2019 Apr; 79(6):633-645. PubMed ID: 30968289
[TBL] [Abstract][Full Text] [Related]
13. Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution.
Khan K; Valeri N; Dearman C; Rao S; Watkins D; Starling N; Chau I; Cunningham D
Crit Rev Oncol Hematol; 2019 Nov; 143():153-163. PubMed ID: 31678702
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the hurdles: surmounting acquired resistance to anti-EGFR therapy in metastatic colorectal cancer.
Sackstein PE; Chintapally N; Wilgucki M; Hartley ML; Alqahtani A; Weinberg BA
Clin Adv Hematol Oncol; 2023 Nov; 21(11):572-583. PubMed ID: 37948593
[TBL] [Abstract][Full Text] [Related]
15. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.
Atkinson CJ; Kawamata F; Liu C; Ham S; Győrffy B; Munn AL; Wei MQ; Möller A; Whitehall V; Wiegmans AP
Mol Oncol; 2019 Apr; 13(4):725-737. PubMed ID: 30478887
[TBL] [Abstract][Full Text] [Related]
16. Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.
Porru M; Pompili L; Caruso C; Biroccio A; Leonetti C
J Exp Clin Cancer Res; 2018 Mar; 37(1):57. PubMed ID: 29534749
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Di Nicolantonio F; Balfour J; Bardelli A
J Natl Cancer Inst; 2009 Oct; 101(19):1308-24. PubMed ID: 19738166
[TBL] [Abstract][Full Text] [Related]
18. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
20. Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer.
Jones J; Ciombor K; Wu C; Bekaii-Saab T; Strickler J
Oncology (Williston Park); 2021 Oct; 35(10):654-660. PubMed ID: 34677922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
